Astrid O Kittang

List of Publications by Year
in descending order

20	726	623734 14	752698 20
papers	citations	h-index	g-index

20	20	20	969
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica, 2007, 92, 332-341.	3.5	129
2	Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. OncoImmunology, 2016, 5, e1062208.	4.6	97
3	The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity. Toxins, 2010, 2, 174-194.	3.4	58
4	Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology, 2010, 84, 239-251.	2.2	50
5	Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets, 2005, 5, 229-248.	1.6	48
6	Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer Journal, 2014, 4, e189-e189.	6.2	48
7	T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunology, Immunotherapy, 2006, 55, 830-840.	4.2	43
8	Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs, 2010, 19, 169-183.	4.1	36
9	The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?. Expert Review of Hematology, 2011, 4, 563-576.	2.2	35
10	Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemiaâ€associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology, 2007, 79, 210-225.	2.2	31
11	The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicineâ€"The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation. Toxins, 2013, 5, 336-362.	3.4	29
12	The protein kinase C agonist PEP005 increases NFâ€ºB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology, 2009, 145, 761-774.	2.5	26
13	Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets, 2008, 8, 666-675.	1.6	18
14	The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2016, 17, 1080.	4.1	16
15	Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. European Journal of Human Genetics, 2018, 26, 858-867.	2.8	14
16	High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 2012, 70, 765-782.	2.3	13
17	In Vitro Induction of a Dendritic Cell Phenotype in Primary Human Acute Myelogenous Leukemia (AML) Blasts Alters the Chemokine Release Profile and Increases the Levels of T Cell Chemotactic CCL17 and CCL22. Journal of Interferon and Cytokine Research, 2008, 28, 297-310.	1.2	11
18	Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. OncoImmunology, 2013, 2, e23138.	4.6	11

#	Article	IF	Citations
19	A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura. Blood Coagulation and Fibrinolysis, 2015, 26, 469-472.	1.0	7
20	Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes. Cancer Immunology, Immunotherapy, 2016, 65, 1135-1147.	4.2	6